Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine Adjunctive to ADT in GAD
NCT04965272Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cariprazine in generalized anxiety disorder (GAD), sponsored by AbbVie Inc.. Planned start Aug 2021; status: withdrawn.
02
Drugs
cariprazine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT04965272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965272.